Connective tissue disease-associated pulmonary arterial hypertension in the modern treatment era.

RATIONALE Pulmonary arterial hypertension in association with connective tissue disease (CTD-PAH) has historically had a poor prognosis, with a 1-year survival rate among patients with systemic sclerosis-associated pulmonary arterial hypertension (SSc-PAH) of 45%. However, more therapies have become available. OBJECTIVES To investigate the survival and characteristics of all patients diagnosed with CTD-PAH in the U.K. pulmonary hypertension service. METHODS National registry of all incident cases of CTD-PAH diagnosed consecutively between January 2001 and June 2006. MEASUREMENTS AND MAIN RESULTS Patients with CTD-PAH (429; 73% SSc-PAH) were diagnosed by a catheter-based approach. One- and 3-year survival rates were 78 and 47% for patients with isolated SSc-PAH. Survival was worse for those with respiratory disease-associated SSc-PAH (3-yr survival, 28%; P = 0.005) whereas survival among patients with exercise-induced SSc-PAH was superior (3-yr survival, 86%; P = < 0.001). Age, sex, mixed venous oxygen saturation, and World Health Organization functional class were independent predictors of survival in isolated SSc-PAH. Nineteen percent of patients with exercise-induced SSc-PAH and 39% of patients with isolated SSc-PAH who were in functional classes I and II had evidence of disease progression. The prevalence of diagnosed SSc-PAH is 2.93 per 1 million. The 3-year survival rate of 75% for those with pulmonary arterial hypertension associated with systemic lupus erythematosus (SLE-PAH) was significantly better than that for patients with SSc-PAH (P = 0.01). CONCLUSIONS Survival of patients with SSc-PAH in the modern treatment era is better than in historical series. A significant proportion of patients with mild functional impairment or exercise-induced SSc-PAH have evidence of disease progression. Survival of patients with respiratory disease-associated pulmonary hypertension is inferior. SLE-PAH has a better prognosis than SSc-PAH.

[1]  G. Simonneau,et al.  Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial , 2008, The Lancet.

[2]  R. Barst,et al.  Sildenafil for pulmonary arterial hypertension associated with connective tissue disease. , 2007, The Journal of rheumatology.

[3]  J. McMurray,et al.  An epidemiological study of pulmonary arterial hypertension , 2007, European Respiratory Journal.

[4]  R. Barst,et al.  Selective endothelinA receptor antagonism with sitaxsentan for pulmonary arterial hypertension associated with connective tissue disease , 2007, Annals of the rheumatic diseases.

[5]  S. Mathai,et al.  Pulmonary hypertension associated with chronic respiratory disease. , 2007, Clinics in chest medicine.

[6]  J. Krishnan,et al.  Clinical differences between idiopathic and scleroderma-related pulmonary hypertension. , 2006, Arthritis and rheumatism.

[7]  M. Humbert,et al.  Immunosuppressive therapy in connective tissue diseases-associated pulmonary arterial hypertension. , 2006, Chest.

[8]  M. Humbert,et al.  Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions , 2006, Annals of the rheumatic diseases.

[9]  M. Humbert,et al.  Pulmonary arterial hypertension in France: results from a national registry. , 2006, American journal of respiratory and critical care medicine.

[10]  Sang-Do Lee,et al.  Clinical aspects of pulmonary hypertension in patients with systemic lupus erythematosus and in patients with idiopathic pulmonary arterial hypertension , 2006, Clinical Rheumatology.

[11]  C. Denton,et al.  Systemic sclerosis associated pulmonary hypertension: improved survival in the current era , 2005, Heart.

[12]  M. Humbert,et al.  Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study. , 2005, Arthritis and rheumatism.

[13]  J. Krishnan,et al.  Long-term outcome of bosentan treatment in idiopathic pulmonary arterial hypertension and pulmonary arterial hypertension associated with the scleroderma spectrum of diseases. , 2005, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[14]  S. Rich,et al.  Treprostinil, a prostacyclin analogue, in pulmonary arterial hypertension associated with connective tissue disease. , 2004, Chest.

[15]  R. Wise,et al.  Scleroderma patients with combined pulmonary hypertension and interstitial lung disease. , 2003, The Journal of rheumatology.

[16]  C. Denton,et al.  Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach , 2003, Annals of the rheumatic diseases.

[17]  F. Saulnier,et al.  Aerosolized iloprost in CREST syndrome related pulmonary hypertension. , 2001, The Journal of rheumatology.

[18]  Stuart Rich,et al.  Continuous Intravenous Epoprostenol for Pulmonary Hypertension Due to the Scleroderma Spectrum of Disease , 2000, Annals of Internal Medicine.

[19]  L. Tam,et al.  Pulmonary hypertension in systemic lupus erythematosus: clinical association and survival in 18 patients. , 1999, The Journal of rheumatology.

[20]  M Abu-Shakra,et al.  Pulmonary hypertension in systemic sclerosis: an analysis of 17 patients. , 1996, British journal of rheumatology.

[21]  T. Medsger,et al.  Pulmonary hypertension in the CREST syndrome variant of systemic sclerosis. , 1986, Arthritis and rheumatism.